Metastatic Colorectal Cancer
Conditions
Brief summary
Collection of real world data on the clinical efficacy of trifluridine/ tipiracil (FTD/TPI) in the Greek population.
Detailed description
The aim of this analysis is to record clinical practice and to collect real world data on the clinical efficacy of trifluridine/ tipiracil (FTD/TPI) in the Greek population. Main objectives include to assess physician's choice of treatment in chemoresistant metastatic colorectal cancer with FTD/TPI in third line and beyond In addition, the clinicopathologic features related to metastatic colorectal cancer (focus on molecular profile), duration of treatment, dose modification and toxicity will be analyzed.
Interventions
DRUGTrifluridine/Tipiracil
Trifluridine/ Tipiracil is an oral combination of an antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase (TPase) inhibitor, tipiracil hydrochloride.
Sponsors
Servier
Hellenic Study Group of Psychoneuroimmunology in Cancer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Age \> 18 years * Histologically confirmed metastatic colorectal cancer * Available data on previous chemotherapy lines
Exclusion criteria
No
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival | Retrospective data analysis from January 2018 to at least 3 months prior to being included in the study. | PFS is defined as the time interval from initiation of treatment to the first date of documented tumor progression or death from any cause, whichever occurs first. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | Retrospective data analysis from January 2018 to at least 3 months prior to being included in the study. | Overall survival is defined as the time interval from initiation of treatment to the date of death due to any cause. |
| Progression Free Survival rate at 6 and 8 months | Retrospective data analysis from January 2018 to at least 3 months prior to being included in the study. | PFS rate at 6 and 8 months corresponding to the percentage of patients surviving without any documented progression of the disease at 6 and 8 months after treatment initiation. |
| Disease Control Rate | Retrospective data analysis from January 2018 to at least 3 months prior to being included in the study. | The DCR is defined as the proportion of patients with objective evidence of complete response (CR), the proportion of patients with objective evidence of partial response (PR), and the proportion of patients with objective evidence of stable disease (SD). |
Countries
Greece
Outcome results
None listed